1. Israel Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Taro Pharmaceutical Industries Ltd.

Taro Pharmaceutical Industries Ltd.

TARO
Taro Pharmaceutical Industries Ltd.US flagNew York Stock Exchange
42.98
USD
+0.01
- -
1.62BMarket Cap
Taro Pharmaceutical Industries Ltd.
TARO
(New York Stock Exchange)

Recent

price

42.98

P/E

ratio

- -

div

yld

- -

ROIC.AI

2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
TTM
FRC
8.39
9.07
9.75
11.39
- -
15.02
17.15
20.15
22.2
21.29
16.48
17.18
16.76
14.37
14.91
15.24
16.25
Revenue per Share
0.78
2.91
1.59
4.11
- -
5.96
8.14
11.31
12.63
11.05
5.26
7.23
6.35
-10.12
1.55
0.68
1.22
Basic EPS, GAAP
1.8
1.5
1.48
3.94
- -
5.34
7.49
9.03
8.78
9.73
7.33
7.52
6.32
0.75
-7.17
0.32
2.29
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
12.82
- -
- -
- -
- -
- -
Dividend per Share
-1.64
1.27
2.83
6.68
- -
13.65
21.92
33.96
46.59
59.37
66.32
63.65
70.88
61.22
63.48
64.25
- -
Book Value per Share
3.4
6.82
8.8
12.26
- -
19.43
22.51
32.28
44.54
49.56
54.35
48.26
54.11
43.67
43.56
43.57
46.88
Tangible Book Value per Share
39
39
40
44
- -
45
44
43
43
41
40
39
38
38
38
38
38
Basic Weighted Avg Shares
329
356
393
506
543
671
759
863
951
879
662
670
645
549
561
573
611
Sales/Revenue/Turnover
14.17
21.13
22.69
40.49
43.74
53.94
57.01
60.66
64.73
58.56
46.06
43.67
38.24
26.44
22.25
3.09
3.6
Operating Margin (%)
21
18
19
19
19
18
17
16
15
15
16
19
21
24
26
32
34
Depreciation Expense
31
114
64
183
204
266
360
484
541
456
211
282
244
-387
58
25
46
Net Income, GAAP
30.73
- -
13.9
11.79
14.93
20.19
18.64
16.51
14.97
18.51
28.03
20.94
17.95
- -
25.16
33.41
38.52
Effective Tax Rate (%)
9.28
32.03
16.32
36.13
37.61
39.68
47.46
56.12
56.9
51.89
31.9
42.06
37.88
-70.43
10.38
4.44
7.48
Profit Margin (%)
-13
59
166
391
- -
717
798
1,204
1,632
1,789
1,681
1,266
1,310
795
906
951
973
Working Capital
58
38
31
28
- -
17
6
5
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
164
296
385
571
- -
891
1,021
1,417
1,937
2,074
2,210
1,911
2,110
1,695
1,711
1,731
1,779
Total Equity
8.96
- -
16.46
32.01
60.2
70.21
41.3
40.76
35.71
24.28
11.65
12.55
11.04
- -
6.1
0.77
1.52
Return on Invested Capital (%)
25.31
- -
34.71
71.43
118.17
83.2
44.14
39.4
31.2
20.46
8.29
10.93
9.37
- -
2.52
1.09
1.06
Return on Capital (%)
- -
- -
78.39
89.06
137.81
87.29
45.61
39.94
31.36
20.52
8.26
10.95
9.38
-15.27
2.46
1.06
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
38
38
38
Market Capitalization
1,426
1,417
1,570

Working Capital

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
Total Current Assets
1,294
1,343
1,347
Cash, Cash Equivalents & STI
806
907
902
Accounts Receivable, Net
227
181
191
Inventories
205
208
215
Total Current Liabilities
385
361
374
Payables & Accruals
59
43
51
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.3%
-4.14%
1.13%
Free Cash Flow
-122.05%
-250.71%
-104.41%
Net Income, GAAP
-39.75%
-81.92%
-56.33%
Sales/Revenue/Turnover
-0.83%
-2.62%
2.07%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
147
132
139
143
561
2023
157
130
139
147
573
2024
159
148
157
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-0.5
0.62
0.7
0.73
1.55
2023
0.37
-0.07
0.19
0.18
0.68
2024
0.27
0.23
0.54
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
Chengdu Huasun Technology Group Inc., Ltd. (000790.SZ)
Talphera, Inc. (TLPH)
Rapid Nutrition PLC (RPNRF)
Dermapharm Holding SE (DMP.DE)
City View Green Holdings Inc. (CVGR.CN)
Haleon plc (HLN)
Business
Taro Pharmaceutical Industries Ltd. develops, manufactures and markets prescription and over-the-counter pharmaceutical products primarily in dermatology, cardiology, pediatrics and neurology; it also produces active pharmaceutical ingredients mainly for use in its finished dosage forms. The company offers generic and branded medications, including topical dermatological products, warfarin sodium tablets and other generics such as those equivalent to Coumadin, Percodan and Percocet; products are sold under Taro's label or private label to wholesalers, retail chains and mass merchandisers in the United States, Canada, Israel and over 25 other countries. Founded in 1950 and headquartered in Haifa Bay, Israel, Taro operates manufacturing and research facilities in Israel, Canada and the United States through subsidiaries like Taro Pharmaceuticals U.S.A. Inc. and Taro Pharmaceuticals Inc.; it became a wholly owned private subsidiary of Sun Pharmaceutical Industries Ltd. following Sun Pharma's acquisition of all outstanding shares in June 2024 for approximately $348 million, delisting it from the New York Stock Exchange.

Company News

APIChatGPT

  • accesswire.com

    FINAL REMINDER TARO DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Taro Pharmaceutical Industries Ltd. Investors to Participate in the Class Action Lawsuit!

  • accesswire.com

    FINAL TARO DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Taro Pharmaceutical Industries Ltd. Investors to Join the Class Action Lawsuit!

  • globenewswire.com

    TARO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Taro Pharmaceutical Industries Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

  • accesswire.com

    TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Taro Pharmaceutical Industries Ltd. to Contact the Firm Today!

  • accesswire.com

    TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Taro Pharmaceutical Industries Ltd. to Contact the Firm Today!

  • accesswire.com

    TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Taro Pharmaceutical Industries Ltd. to Contact the Firm Today!

  • accesswire.com

    TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!

  • accesswire.com

    TARO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Shareholders Have Opportunity to Lead Class Action Lawsuit!

  • globenewswire.com

    TARO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Taro Pharmaceutical Industries Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

  • accesswire.com

    TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Stockholders Have Opportunity to Lead Class Action Lawsuit!

  • accesswire.com

    TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Shareholders Have Opportunity to Lead Class Action Lawsuit!

  • accesswire.com

    TARO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Investors Have Opportunity to Lead Class Action Lawsuit!

  • accesswire.com

    TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

  • accesswire.com

    TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

  • globenewswire.com

    TARO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Taro Pharmaceutical Industries Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

  • accesswire.com

    TARO STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

  • accesswire.com

    TARO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

  • accesswire.com

    TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

  • globenewswire.com

    TARO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Taro Pharmaceutical Industries Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

  • accesswire.com

    TARO Investors Have Opportunity to Lead Taro Pharmaceutical Industries Ltd. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!